Conclusion
Pharmacovigilance- Adverse drug reaction monitoring
Article REF: PHA3060 V1
Conclusion
Pharmacovigilance- Adverse drug reaction monitoring

Author : Elisabeth POLARD

Publication date: June 10, 2016, Review date: May 27, 2020 | Lire en français

Logo Techniques de l'Ingenieur You do not have access to this resource.
Request your free trial access! Free trial

Already subscribed?

8. Conclusion

Pharmacovigilance data contribute to the ongoing reassessment of the risk/benefit ratio of drugs in real-life prescribing situations. On an individual level, it helps to choose the best drug for a given patient; on a population level, it leads to the decision whether or not to keep a drug on the market, or to inform healthcare professionals and the public of the potential risk.

Pharmacovigilance is more than just a monitoring activity. It is part of a wider process of preventing and assessing drug risk in the day-to-day practice of healthcare professionals. It is an integral part of quality and risk management processes. The development of epidemiological studies, as a complement to existing vigilance systems and the active search for signals, provides a global view of the real-life safety profile of drugs.

According to Prescrire, public...

You do not have access to this resource.
Logo Techniques de l'Ingenieur

Exclusive to subscribers. 97% yet to be discovered!

You do not have access to this resource. Click here to request your free trial access!

Already subscribed?


Article included in this offer

"Drugs and pharmaceuticals"

( 125 articles )

Complete knowledge base

Updated and enriched with articles validated by our scientific committees

Services

A set of exclusive tools to complement the resources

View offer details
Contact us